These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26331445)

  • 1. Ignorance is not bliss: Statistical power is not probability of trial success.
    Zierhut ML; Bycott P; Gibbs MA; Smith BP; Vicini P
    Clin Pharmacol Ther; 2016 Apr; 99(4):356-9. PubMed ID: 26331445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empirical shrinkage estimator for consistency assessment of treatment effects in multi-regional clinical trials.
    Quan H; Li M; Shih WJ; Ouyang SP; Chen J; Zhang J; Zhao PL
    Stat Med; 2013 May; 32(10):1691-706. PubMed ID: 22855311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size and the probability of a successful trial.
    Chuang-Stein C
    Pharm Stat; 2006; 5(4):305-9. PubMed ID: 17128428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size reestimation by Bayesian prediction.
    Wang MD
    Biom J; 2007 Jun; 49(3):365-77. PubMed ID: 17623342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating and utilizing probability of study success in clinical development.
    Wang Y; Fu H; Kulkarni P; Kaiser C
    Clin Trials; 2013; 10(3):407-13. PubMed ID: 23471634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian predictive power: choice of prior and some recommendations for its use as probability of success in drug development.
    Rufibach K; Burger HU; Abt M
    Pharm Stat; 2016 Sep; 15(5):438-46. PubMed ID: 27442271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical approaches for conducting network meta-analysis in drug development.
    Jones B; Roger J; Lane PW; Lawton A; Fletcher C; Cappelleri JC; Tate H; Moneuse P;
    Pharm Stat; 2011; 10(6):523-31. PubMed ID: 22213533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.
    Nixon RM; O'Hagan A; Oakley J; Madan J; Stevens JW; Bansback N; Brennan A
    Pharm Stat; 2009; 8(4):371-89. PubMed ID: 19340851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collection, synthesis, and interpretation of evidence: a proof-of-concept study in COPD.
    Di Scala L; Kerman J; Neuenschwander B
    Stat Med; 2013 May; 32(10):1621-34. PubMed ID: 23303622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian statistical methods in public health and medicine.
    Etzioni RD; Kadane JB
    Annu Rev Public Health; 1995; 16():23-41. PubMed ID: 7639872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using prior information to allocate significance levels for multiple endpoints.
    Westfall PH; Krishen A; Young SS
    Stat Med; 1998 Sep; 17(18):2107-19. PubMed ID: 9789917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Count on your beliefs. Bayes--not the P value--measures credence].
    Taube A; Malmquist J
    Lakartidningen; 2001 Jul; 98(28-29):3208-11. PubMed ID: 11496808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive probability of success using surrogate endpoints.
    Saint-Hilary G; Barboux V; Pannaux M; Gasparini M; Robert V; Mastrantonio G
    Stat Med; 2019 May; 38(10):1753-1774. PubMed ID: 30548627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the success probability of a Phase III clinical trial based on Phase II data.
    Su Z
    Contemp Clin Trials; 2010 Nov; 31(6):620-3. PubMed ID: 20713180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian clinical trials.
    Berry DA
    Nat Rev Drug Discov; 2006 Jan; 5(1):27-36. PubMed ID: 16485344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detecting potential safety issues in clinical trials by Bayesian screening.
    Gould AL
    Biom J; 2008 Oct; 50(5):837-51. PubMed ID: 18932142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Roaming through methodology. XXXVI. Likelihood ratios and Bayes' rule].
    Vermeulen M
    Ned Tijdschr Geneeskd; 2001 Dec; 145(50):2421-4. PubMed ID: 11776667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A flexible Bayesian approach for modeling monotonic dose-response relationships in drug development trials.
    Ohlssen D; Racine A
    J Biopharm Stat; 2015; 25(1):137-56. PubMed ID: 24836192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel metric to assess the clinical utility of a drug in the presence of efficacy and dropout information.
    Goyal N; Gomeni R
    Clin Pharmacol Ther; 2012 Feb; 91(2):215-9. PubMed ID: 22089266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.